ITB-MED, founded in 2016, has grown to over 40 employees across offices in Stockholm and New York. Clinical trials are being conducted globally, with a particular focus on the United States (US) and the European Union (EU), aiming to submit applications for the market authorization of siplizumab. We have expanded rapidly, and in 2024, our Swedish office relocated to a combined lab and office space in “Forskaren,” Stockholm’s new life science center.